NVP-HDM201 is an orally bioavailable, potent and selective inhibitor of p53-MDM2 interaction, binding to human MDM2 protein with a picomolar Ki value (0.21 nM). Highly selective against MDM4 protein (Ki = 3300 nM, >10000 fold selectivity). It activates p53 and induces robust p53-dependent cell cycle arrest and apoptosis in human p53 wild-type tumor cells. Its activity and selectivity have been tested and confirmed in both in vitro and in vivo. Application of NVP-HDM201 using various dosing schedules triggers rapid and sustained activation of p53-dependent pharmacodynamics biomarkers resulting in tumor regression in multiple xenorgrafted models of p53 wild-type human cancers.

KEYWORDS: NVP-HDM201 | Supplier | MDM2 inhibitor | Siremadlin | HDM-201 | NVP-HDM-201 | NVP-HDM 201 | CT-HDM201 | CAS [1448867-41-1] | p53 | HDM-MDM | Inhibitor | Enzymes